Mechanisms of Endothelial Dysfunction in Pre-eclampsia and Gestational Diabetes Mellitus: Windows Into Future Cardiometabolic Health?
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Placental insufficiency and adipose tissue dysregulation are postulated to play key roles in the pathophysiology of both pre-eclampsia (PE) and gestational diabetes mellitus (GDM). A dysfunctional release of deleterious signaling motifs can offset an increase in circulating oxidative stressors, pro-inflammatory factors and various cytokines. It has been previously postulated that endothelial dysfunction, instigated by signaling from endocrine organs such as the placenta and adipose tissue, may be a key mediator of the vasculopathy that is evident in both adverse obstetric complications. These signaling pathways also have significant effects on long term maternal cardiometabolic health outcomes, specifically cardiovascular disease, hypertension, and type II diabetes. Recent studies have noted that both PE and GDM are strongly associated with lower maternal flow-mediated dilation, however the exact pathways which link endothelial dysfunction to clinical outcomes in these complications remains in question. The current diagnostic regimen for both PE and GDM lacks specificity and consistency in relation to clinical guidelines. Furthermore, current therapeutic options rely largely on clinical symptom control such as antihypertensives and insulin therapy, rather than that of early intervention or prophylaxis. A better understanding of the pathogenic origin of these obstetric complications will allow for more targeted therapeutic interventions. In this review we will explore the complex signaling relationship between the placenta and adipose tissue in PE and GDM and investigate how these intricate pathways affect maternal endothelial function and, hence, play a role in acute pathophysiology and the development of future chronic maternal health outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 1×
“Whereas, VEGF can bind to various receptors including VEGFR-1, 2, and 3, PIGF specifically signals through VEGFR-1 (or Flt-1) binding (155).”
BackgroundInflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199 · cited 1×
“Insulin Resistance and Altered Lipid Signaling In the last decade there has been a significant increase in our understanding of the pathogenic role of adipose tissue inflammation in mediating the pathophysiology of atherosclerosis and vascular damage and the disruption of insulin signaling with resulting insulin resis…”
BackgroundBrown Adipose Tissue: Function and Physiological Significance
CANNON, B., & NEDERGAARD, J. (2004) · Physiological Reviews · doi:10.1152/physrev.00015.2003 · Cited by 6,433 · cited 1×
“Brown adipose tissue (BAT) is distinct from white adipose tissue (WAT) in that their more abundant mitochondria profoundly express uncoupling protein 1 (UCP1), which uncouples substrate oxidation from ATP production so that heat can be produced (92).”
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101 · cited 1×
“sFlt-1 is released from the placenta in response to oxidative stress and inflammation (157) and the increased level of sFlt-1 is associated with detrimental alterations in endothelial integrity (158).”
BackgroundThe NLRP3 Inflammasome: an overview of mechanisms of activation and regulation
Kelley, N., Jeltema, D., Duan, Y., & He, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133328 · Cited by 3,539 · cited 1×
“The NLRP3 inflammasome is activated by a diverse range of stimuli including products of mitochondrial dysfunction and ROS (207).”
BackgroundAdipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.
Guilherme, A., Virbasius, J. V., Puri, V., & Czech, M. P. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2391 · Cited by 2,292
Inflammation in Atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.009 · Cited by 2,228 · cited 1×
“Other pro-inflammatory mediators including resistin, TNF-α, IL-6 and IL-1β also exert an adverse effect on the vasculature by promoting insulin resistance and monocyte infiltration of the endothelium (118), resulting in chronic inflammation and endothelial damage.”
BackgroundRana (2019) · doi:10.1161/circresaha.118.313276 · Cited by 2,095
Brown, M. A., Magee, L. A., Kenny, L. C., Karumanchi, S. A., McCarthy, F. P., Saito, S., Hall, D. R., Warren, C. E., Adoyi, G., & Ishaku, S. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10803 · Cited by 2,089
Self-citationTargeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.97 · Cited by 1,885
The Pathophysiology of Gestational Diabetes Mellitus
Plows, J. F., Stanley, J. L., Baker, P. N., Reynolds, C. M., & Vickers, M. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113342 · Cited by 1,874 · cited 1×
“As the fetus develops, a surge of hormone secretion, such as placental lactogen and estrogen, promote a state of insulin resistance, which facilitates a rise in blood glucose levels to fuel fetal growth (9).”
BackgroundIncalza, M. A., D'Oria, R., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2017.05.005 · Cited by 1,356
Damage-associated molecular patterns in inflammatory diseases
Roh, J. S., & Sohn, D. H. (2018) · Immune Network · doi:10.4110/in.2018.18.e27 · Cited by 1,261
Pre-eclampsia: pathophysiology and clinical implications
Burton, G. J., Redman, C. W., Roberts, J. M., & Moffett, A. (2019) · BMJ · doi:10.1136/bmj.l2381 · Cited by 1,250
New mitochondrial DNA synthesis enables NLRP3 inflammasome activation
Zhong, Z., Liang, S., Sanchez-Lopez, E., He, F., Shalapour, S., Lin, X.-J., Wong, J., Ding, S., Seki, E., Schnabl, B., et al. (2018) · Nature · doi:10.1038/s41586-018-0372-z · Cited by 1,208
The Role of Nitric Oxide on Endothelial Function
Tousoulis, D., Kampoli, A.-M., Tentolouris Nikolaos Papageorgiou, C., & Stefanadis, C. (2012) · Current Vascular Pharmacology · doi:10.2174/157016112798829760 · Cited by 1,012
Bartsch, E., Medcalf, K. E., Park, A. L., & Ray, J. G. (2016) · BMJ · doi:10.1136/bmj.i1753 · Cited by 996
ROS Generation and Antioxidant Defense Systems in Normal and Malignant Cells
Snezhkina, A. V., Kudryavtseva, A. V., Kardymon, O. L., Savvateeva, M. V., Melnikova, N. V., Krasnov, G. S., & Dmitriev, A. A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/6175804 · Cited by 934 · cited 1×
“Mitochondria serve as the primary source of endogenous ROS, however the endoplasmic reticulum and peroxisomes also function in ROS production (38).”
BackgroundEpidemiology of gestational diabetes mellitus and its association with Type 2 diabetes
Ben‐Haroush, A., Yogev, Y., & Hod, M. (2004) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00985.x · Cited by 856
Glyburide inhibits the Cryopyrin/Nalp3 inflammasome
Lamkanfi, M., Mueller, J. L., Vitari, A. C., Misaghi, S., Fedorova, A., Deshayes, K., Lee, W. P., Hoffman, H. M., & Dixit, V. M. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200903124 · Cited by 820 · cited 1×
“Both in vitro and in vivo studies suggest that glyburide inhibits activation upstream of NLRP3 and more recently has been proposed to inhibit the NEK7-NLRP3 interaction (209, 210).”
BackgroundAngiogenesis modulates adipogenesis and obesity
Cao, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32239 · Cited by 736 · cited 1×
“Maternal obesity may affect these anti-angiogenic factors via a number of adipokine-mediated pathways (165) but their crosstalk is poorly characterized in human pregnancies.”
BackgroundObesity in Pregnancy Stimulates Macrophage Accumulation and Inflammation in the Placenta
Challier, J. C., Basu, S., Bintein, T., Minium, J., Hotmire, K., Catalano, P. M., & Hauguel-de Mouzon, S. (2008) · Placenta · doi:10.1016/j.placenta.2007.12.010 · Cited by 712 · cited 1×
“reported that obesity in pregnant women resulted in a 2–3-fold increase in the number of placental macrophages, characterized by an increase in IL-1, TNF-α, and IL-6 mRNA expression (114).”
BackgroundPharmacological Inhibitors of the NLRP3 Inflammasome
Zahid, A., Li, B., Kombe, A. J. K., Jin, T., & Tao, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02538 · Cited by 671 · cited 2×
“A similar sulfonylurea compound, MCC950, is considered one of the most selective and potent NLRP3 inhibitors (212).”
BackgroundAdipokine dysregulation and adipose tissue inflammation in human obesity
Unamuno, X., Gómez‐Ambrosi, J., Rodríguez, A., Becerril, S., Frühbeck, G., & Catalán, V. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12997 · Cited by 610
Lee, K. W., Ching, S. M., Ramachandran, V., Yee, A., Hoo, F. K., Chia, Y. C., Wan Sulaiman, W. A., Suppiah, S., Mohamed, M. H., & Veettil, S. K. (2018) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-018-2131-4 · Cited by 546
Mitochondria and Endothelial Function
Kluge, M. A., Fetterman, J. L., & Vita, J. A. (2013) · Circulation Research · doi:10.1161/circresaha.111.300233 · Cited by 508 · cited 3×
“This process resulted in a down regulation of specific target genes, including sFlt-1 in HCAEC, in response to both normal and PE EV-treatment (89), suggesting that EVs may be initiators rather than modifiers of the disease.”
BackgroundParsons, J. A. (1992) · Endocrinology · doi:10.1210/en.130.3.1459 · Cited by 476 · cited 1×
“Appropriate blood glucose levels are then maintained through homeostatic mechanisms such as hypertrophy and hyperplasia of pancreatic β-cells (10).”
BackgroundErratum: Targeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.149 · Cited by 465
Rossman, M. J., Santos-Parker, J. R., Steward, C. A. C., Bispham, N. Z., Cuevas, L. M., Rosenberg, H. L., Woodward, K. A., Chonchol, M., Gioscia-Ryan, R. A., Murphy, M. P., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10787 · Cited by 456 · cited 2×
“In addition, a clinical trial of chronic MitoQ administration in healthy older adults has established a favorable outcome in reducing markers of vasculopathy and inflammation (197).”
BackgroundThe discovery of placenta growth factor and its biological activity
De Falco, S. (2012) · Experimental and Molecular Medicine · doi:10.3858/emm.2012.44.1.025 · Cited by 425
Gane, E. J., Weilert, F., Orr, D. W., Keogh, G. F., Gibson, M., Lockhart, M. M., Frampton, C. M., Taylor, K. M., Smith, R. A. J., & Murphy, M. P. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02250.x · Cited by 379 · cited 1×
“The CLEAR trial, treating Hepatitis C patients with MitoQ, showed a decrease in circulating markers of liver damage and was the first report of mitochondrial-targeted antioxidant clinical efficacy and safety (199).”
MethodEvidence for altered placental blood flow and vascularity in compromised pregnancies
Reynolds, L. P., Caton, J. S., Redmer, D. A., Grazul‐Bilska, A. T., Vonnahme, K. A., Borowicz, P. P., Luther, J. S., Wallace, J. M., Wu, G., & Spencer, T. E. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2005.104430 · Cited by 358
The unusual amino acid L-ergothioneine is a physiologic cytoprotectant
Paul, B. D., & Snyder, S. H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.163 · Cited by 304
Gioscia‐Ryan, R. A., LaRocca, T. J., Sindler, A. L., Zigler, M. C., Murphy, M. P., & Seals, D. R. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2013.268680 · Cited by 263 · cited 1×
“MitoQ has ameliorated endothelial dysfunction and improved vascular function in recent animal and human studies (196, 197).”
BackgroundWilliams, M. A., Qiu, C., Muy-Rivera, M., Vadachkoria, S., Song, T., & Luthy, D. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031201 · Cited by 220
Leptin-induced endothelial dysfunction in obesity
Korda, M., Kubant, R., Patton, S., & Malinski, T. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00479.2008 · Cited by 213
Gunderson, E. P., Chiang, V., Pletcher, M. J., Jacobs, D. R., Quesenberry, C. P., Sidney, S., & Lewis, C. E. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000490 · Cited by 182
Grieger, J. A., Bianco-Miotto, T., Grzeskowiak, L. E., Leemaqz, S. Y., Poston, L., McCowan, L. M., Kenny, L. C., Myers, J. E., Walker, J. J., Dekker, G. A., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002710 · Cited by 182 · cited 1×
“Additionally, PE and GDM are, themselves, established risk factors for future poor cardiovascular health outcomes (30).”
BackgroundAdverse pregnancy outcomes and future maternal cardiovascular disease
Hauspurg, A., Ying, W., Hubel, C. A., Michos, E. D., & Ouyang, P. (2018) · Clinical Cardiology · doi:10.1002/clc.22887 · Cited by 179 · cited 1×
“A shift in glucose metabolism, during which maternal hyperinsulinemia is compensated to support the need of fetal growth, serves as a cardiometabolic stressor that may culminate in CVD co-morbidities or long-term cardiovascular complications (3).”
BackgroundRetnakaran, R., & Shah, B. R. (2017) · Diabetes Care · doi:10.2337/dc16-1400 · Cited by 167
Obesity: a risk factor for preeclampsia
Walsh, S. W. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2007.09.003 · Cited by 155
Weel, I. C., Baergen, R. N., Romão-Veiga, M., Borges, V. T., Ribeiro, V. R., Witkin, S. S., Bannwart-Castro, C., Peraçoli, J. C., De Oliveira, L., & Peraçoli, M. T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157584 · Cited by 131
Syncytial Knots (Tenney-Parker Changes) in the Human Placenta
Fogarty, N. M. E., Ferguson-Smith, A. C., & Burton, G. J. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.03.016 · Cited by 116 · cited 1×
“These syncytial knots are formed from abundant syncytiotrophoblast aggregation at the surface of placental terminal villi and are believed to be a marker of oxidative damage (164).”
BackgroundShostrom, D. C. V., Sun, Y., Oleson, J. J., Snetselaar, L. G., & Bao, W. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00144 · Cited by 96
p53 and mitochondrial dysfunction: novel insight of neurodegenerative diseases
Dai, C.-Q., Luo, T.-T., Luo, S.-C., Wang, J.-Q., Wang, S.-M., Bai, Y.-H., Yang, Y.-L., & Wang, Y.-Y. (2016) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-016-9669-5 · Cited by 93
Nlrp3 Inflammasome Activation in Type 2 Diabetes: Is It Clinically Relevant?
Dixit, V. D. (2013) · Diabetes · doi:10.2337/db12-1115 · Cited by 85
Oxidative Stress and Obesity: The Chicken or the Egg?
Aroor, A. R., & DeMarco, V. G. (2014) · Diabetes · doi:10.2337/db14-0424 · Cited by 85
Cited by
The role of immune cells and mediators in preeclampsia
Deer, E., Herrock, O., Campbell, N., Cornelius, D., Fitzgerald, S., Amaral, L. M., & LaMarca, B. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00670-0 · Cited by 290
Gestational Diabetes Mellitus and Preeclampsia: Correlation and Influencing Factors
Yang, Y., & Wu, N. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.831297 · Cited by 155
“Moreover, in both GDM and PE, the pathophysiological processes involve oxidative stress, pro-inflammatory factor release, vascular endothelial dysfunction (3, 4), which all increase the risk of future maternal diabetes and cardiovascular disease (5–8); thus, a correlation between GDM and PE may exist.”
BackgroundVitamin C supplementation for diabetes management: A comprehensive narrative review
Mason, S. A., Parker, L., van der Pligt, P., & Wadley, G. D. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.12.003 · Cited by 53
Syama, K. P., Blais, E., & Kumarathasan, P. (2025) · Science of The Total Environment · doi:10.1016/j.scitotenv.2025.178999 · Cited by 39
Metadata
- Authors
- McElwain, C. J., Tuboly, E., McCarthy, F. P., & McCarthy, C. M.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2020-09-11
- Volume
- 11
- Pages
- 655-655
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W3086407586
- Cited by
- 208
- References
- 48
- FWCI
- 10.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.